Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Ther. 2006 Apr;13(4):644-70. Epub 2006 Feb 14.

Progress towards in vivo use of siRNAs.

Author information

1
Integrated DNA Technologies, Inc., Coralville, IA 52241, USA. mbehlke@idtdna.com

Abstract

RNA interference (RNAi) has become the method of choice to suppress gene expression in vitro. It is also emerging as a powerful tool for in vivo research with over 90 studies published using synthetic small interfering RNAs in mammals. These reports demonstrate the potential for use of synthetic small interfering RNAs (siRNAs) as therapeutic agents, especially in the areas of cancer and viral infection. The number of reports using siRNAs for functional genomics applications, for validation of targets for small-molecule drug development programs, and to address questions of basic biology will rapidly grow as methods and protocols for use in animals become more established. This review will first discuss aspects of RNAi biochemistry and biology that impact in vivo use, especially as relates to experimental design, and will then provide an overview of published work with a focus on methodology.

PMID:
16481219
DOI:
10.1016/j.ymthe.2006.01.001
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center